Targeted therapy with imatinib, a selective tyrosine-kinase inhibitor of KIT, PDGFRA, and ABL, revolutionized treatment and was approved for first-line treatment for advanced GIST in 2002 and for adjuvant treatment in high-risk patients in 20087–9. The gene discussed is KIT; the disease is gastrointestinal stromal tumor.